These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10444285)

  • 21. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
    Lambert T; Guérois C; Gay V; Stieltjes N; Bertrand MA; Derlon A; Sigaud M; Hassoun A; Négrier C; Coatmelec B; Dreyfus M; Dubanchet A
    Haemophilia; 2007 Jul; 13(4):357-60. PubMed ID: 17610548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
    Iannazzo S; Cortesi PA; Crea R; Steinitz K; Mantovani LG; Gringeri A
    Blood Coagul Fibrinolysis; 2017 Sep; 28(6):425-430. PubMed ID: 27898515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
    Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
    Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
    Revel-Vilk S; Blanchette VS; Schmugge M; Clark DS; Lillicrap D; Rand ML
    Haemophilia; 2010 Jan; 16(1):72-9. PubMed ID: 19765092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
    Pabinger I; Mamonov V; Windyga J; Engl W; Doralt J; Tangada S; Spotts G; Ewenstein B
    Haemophilia; 2021 May; 27(3):e331-e339. PubMed ID: 33772963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery.
    Batorova A; Martinowitz U
    Br J Haematol; 2000 Sep; 110(3):715-20. PubMed ID: 10997985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia.
    Srivastava A; Chandy M; Sunderaj GD; Lee V; Daniel AJ; Dennison D; Nair SC; Mathews V; Anderson G; Nair A; Moses BV; Sudarsanam A
    Haemophilia; 1998 Nov; 4(6):799-801. PubMed ID: 10028300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
    Auerswald G; Bade A; Johne J; Haubold K; Overberg D; Masurat S; Moorthi C
    Thromb Res; 2014 Nov; 134 Suppl 1():S43-7. PubMed ID: 24360932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre.
    Mulcahy R; Walsh M; Scully MF
    Haemophilia; 2005 May; 11(3):208-15. PubMed ID: 15876265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors.
    Kasuda S; Tanaka I; Shima M; Matsumoto T; Sakurai Y; Nishiya K; Giles AR; Yoshioka A
    Haemophilia; 2004 Jul; 10(4):341-6. PubMed ID: 15230947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
    Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
    Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.